Overview

• In mouse studies, the vaccine prevented melanoma, pancreatic, and triple‑negative breast cancers and also cleared existing tumors in some cases.
• Tumor rejection rates reached 88% in pancreatic cancer, 75% in triple‑negative breast cancer, and 69% in melanoma when using a tumor‑lysate formulation.
• In a prophylactic melanoma challenge, 80% of vaccinated mice stayed tumor‑free and survived to the 250‑day endpoint, while control groups did not survive beyond 35 days.
• None of the vaccinated mice developed lung metastases, whereas unvaccinated or control mice did.
• The peer‑reviewed results were published in Cell Reports Medicine, and the researchers say the platform is being advanced toward therapeutic vaccine development.